PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1096412
PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1096412
North America psychedelic drugs market is projected to register a substantial CAGR of 13.4% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021 and the forecast period is 2022 to 2029.
North America Global Psychedelic Drugs Market, By Source (Synthetic & Natural), Type (Empathogens, Dissociatives & Others), Drugs (Gamma-Hydroxybutyric Acid, Ketamine, Psilocybin, Others), Application (Narcolepsy, Treatment Resistant Depression, Major Depressive Disorder, Opiate Addiction, Post-Traumatic Stress Disorder, Others), Route of Administration (Oral, Inhalation, Injectable), End User (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy)
Country (U.S., Canada, Mexico and Rest of North America) Industry Trends and Forecast to 2029.
Due to increasing prevalence of depression and mental disorder
Growing Acceptance Of Psychedelic Drugs For Treating Depression
Jazz Pharmaceuticals, Inc.
Janssen Global Services, LLC (a subsidiary of Johnson & Johnson Services, Inc.)
Hikma Pharmaceuticals PLC
COMPASS
Pfizer Inc.
Avadel
Cybin Corp.
Entheon Biomedical Corp
PharmaTher Holdings Ltd.
NRx Pharmaceuticals, Inc.
usonainstitute.org